Related Experiment Video
Updated: Aug 16, 2025
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
Protein-Based Oncopanel as Addition to Target Sequencing in Head and Neck Squamous Cell Carcinoma to Individualize
Adrian von Witzleben1, Urs Müller-Richter2, Katja Maurus3
1Department of Otorhinolaryngology and Head & Neck Surgery, Head and Neck Cancer Center of the Comprehensive Cancer Center Ulm, University Medical Center Ulm, 89075 Ulm, Germany.
Abstract:
Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous group of cancers and patients have limited therapy options if primary treatment fails. Therefore, additional information about the biology of the tumor is essential. Here we performed a feasibility study of concurrently applying two precision diagnostic tools in a consecutive series of HNSCC patients. We analyzed tumor samples of 31 patients using a genomic (oncomine) and a proteomic, immunohistochemical approach (oncopanel) and compared the result, also in the focus on their overlapping therapeutical targets. We found no strong correlation between the two approaches and observed a higher proportion of marker expression for the immunohistochemical panel. However, both panels show in our HNSCC cohort distinct patterns with druggable targets. The data suggest that both approaches complement one another and can be applied side-by-side to identify the best targets for the development of individual treatment options for HNSCC patients.
Insights
Precision diagnostics for head and neck squamous cell carcinoma (HNSCC) show distinct druggable targets. Combining genomic and proteomic approaches may improve personalized HNSCC treatment options.
Area of Science:
- Oncology
- Genomics
- Proteomics
- Precision Medicine
Background:
- Head and neck squamous cell carcinoma (HNSCC) is a complex disease with limited therapeutic options upon treatment failure.
- Understanding tumor biology is crucial for developing effective, individualized treatment strategies for HNSCC patients.
Purpose of the Study:
- To assess the feasibility of concurrently applying genomic and proteomic diagnostic tools in HNSCC patients.
- To compare results from genomic (Oncomine) and proteomic (Oncopanel) approaches, focusing on overlapping therapeutic targets.
Main Methods:
- Tumor samples from 31 consecutive HNSCC patients were analyzed.
- Genomic analysis was performed using the Oncomine platform.
- Proteomic analysis utilized an immunohistochemical approach (Oncopanel).
Main Results:
- No strong correlation was observed between the genomic and proteomic approaches.
- The immunohistochemical panel revealed a higher proportion of marker expression compared to the genomic panel.
- Both diagnostic panels identified distinct patterns of druggable targets within the HNSCC cohort.
Conclusions:
- Genomic and proteomic approaches provide complementary information for HNSCC.
- Concurrent application of these tools can identify unique therapeutic targets.
- This combined strategy aids in developing personalized treatment options for HNSCC patients.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...